Kythera is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Kythera’s lead product candidate, ATX-101, is a potential first-in-class, injectable drug currently in Phase III clinical development for the reduction of submental fat.
- Sector : Healthcare
- Status : Public (NASDAQ: KYTH)
- Geographic Market : U.S.
- Investment Year : 2012
- Investment Team : Abhijeet Lele, Ashley Friedman, Yuriy Prilutskiy